Cutia Therapeutics (2487) AI Stock Analysis

• Market Cap: HK$2.32B
• Dividend Yield: N/A
• Average Volume (3M): 394.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.18
• Revenue Growth: 25.89%
• EPS Growth: 12.90%
• Country: HK
• Employees: 333
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 364,730,870
• 10 Day Avg. Volume: 338,660
• 30 Day Avg. Volume: 394,853
• PEG Ratio: 0.06
• Price to Book (P/B): 2.00
• Price to Sales (P/S): 6.98
• P/FCF Ratio: -4.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -9.42
• Revenue Forecast (FY): HK$3.22B

• Rating: 41 Neutral
• Price Target: HK$8.50 ▲(3.41% Upside)

Cutia Therapeutics faces significant challenges with profitability and cash flow, reflected in a low financial performance score. Technical indicators show bearish momentum, and the negative P/E ratio highlights valuation difficulties. These factors collectively result in a low overall stock score.

Cutia Therapeutics Business Overview & Revenue Model

Company Description

Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company was incorporated in 2019 and is based in Shanghai, China with additional offices in Beijing, Wuxi and Hong Kong.

How the Company Makes Money

Cutia Therapeutics generates revenue primarily through the sale of its pharmaceutical products, which are marketed to healthcare providers and institutions. The company also engages in strategic partnerships with other biotech firms and pharmaceutical companies, allowing for collaborative research and development efforts, as well as sharing of resources and expertise. Additionally, Cutia may benefit from milestone payments and royalties from licensing agreements related to its proprietary technologies and drug candidates. Grants and funding from public or private entities may also contribute to its revenue, especially during the research and development phases of its products.

Cutia Therapeutics Financial Statement Overview

Summary

Cutia Therapeutics is experiencing significant revenue growth, but faces substantial losses with negative net income and EBIT margins. While the balance sheet shows a strong equity position, cash flow challenges persist, impacting financial flexibility.

Income Statement

Cutia Therapeutics shows significant revenue growth, with a notable increase from 2021 to 2024. However, the company is experiencing substantial losses, as indicated by negative net income and EBIT margins. The gross profit margin is positive, but the net profit margin remains negative, highlighting ongoing profitability challenges.

Balance Sheet

The balance sheet reflects a strong equity position with a positive stockholders' equity in 2024, recovering from negative equity in previous years. The debt-to-equity ratio is relatively low, indicating manageable leverage. However, the company has faced fluctuating equity levels, which could pose risks if not stabilized.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, indicating cash management challenges. Despite improvements in free cash flow from 2023 to 2024, the company still faces difficulties in generating positive cash flow, which could impact its financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	250.33M	279.62M	137.62M	11.37M	2.04M
Gross Profit	125.19M	143.46M	71.01M	7.94M	1.61M
EBITDA	-422.82M	-430.69M	-1.92B	-535.19M	-309.23M
Net Income	-472.27M	-433.81M	-1.96B	-555.84M	-319.58M
Balance Sheet
Total Assets	1.12B	1.39B	1.71B	1.45B	1.49B
Cash, Cash Equivalents and Short-Term Investments	681.51M	876.15M	1.27B	1.08B	1.38B
Total Debt	290.40M	320.94M	243.75M	54.13M	26.53M
Total Liabilities	359.62M	418.51M	357.76M	2.69B	2.29B
Stockholders Equity	756.62M	974.73M	1.35B	-1.25B	-790.51M
Cash Flow
Free Cash Flow	-209.64M	-468.66M	-437.23M	-371.50M	-185.76M
Operating Cash Flow	-196.82M	-442.98M	-381.31M	-236.19M	-159.88M
Investing Cash Flow	272.88M	316.07M	-203.58M	462.06M	-410.65M
Financing Cash Flow	32.50M	37.84M	588.32M	-10.25M	480.76M

Cutia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2487, the sentiment is Negative. The current price of 8.22 is above the 20-day moving average (MA) of 7.74, below the 50-day MA of 8.94, and above the 200-day MA of 7.72, indicating a bearish trend. The MACD of -0.66 indicates Positive momentum. The RSI at 19.68 is Positive, neither overbought nor oversold. The STOCH value of 9.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2487.

Cutia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1873	51 Neutral	HK$4.88B	26.46	4.45%	―	-8.11%	―
3681	45 Neutral	HK$2.27B	―	-55.33%	―	-100.00%	30.68%
2616	42 Neutral	HK$8.81B	-19.44	-95.84%	―	-55.64%	-158.67%
2487	41 Neutral	HK$2.32B	―	-48.42%	―	25.89%	12.90%
2179	41 Neutral	HK$3.26B	―	-129.05%	―	―	-18.99%
1167	40 Underperform	HK$5.49B	-109.29	-5.08%	―	770.20%	87.27%

Cutia Therapeutics Corporate Events

Cutia Therapeutics Completes HK$240 Million Share Placement

Cutia Therapeutics has successfully completed the placement of 28,904,000 new shares under a general mandate, raising approximately HK$240.27 million in net proceeds. The funds will be used to advance the company’s research and development pipeline, particularly in areas such as localized adipose accumulation management and skin diseases, as well as to deploy necessary production facilities and equipment.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics to Raise HK$240 Million Through Share Placement

Cutia Therapeutics announced the placement of 28,904,000 new shares under a general mandate, representing approximately 9.05% of its issued shares. The shares are priced at HK$8.40 each, generating estimated net proceeds of HK$240.26 million. This strategic move is expected to enhance the company’s financial position and support its ongoing growth in the dermatology sector.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics Announces Board Changes

Cutia Therapeutics, a company incorporated in the Cayman Islands, has announced changes in its board of directors. Mr. Tao Tak Yan Dennis has resigned from his position as an independent non-executive director and from his roles in the audit and nomination committees to focus on personal commitments. The company has appointed Mr. Zhang Zhisong as the new independent non-executive director, effective August 28, 2025. Mr. Zhang brings extensive financial experience from previous roles at TUHU Car Inc., Goldman Sachs, Citigroup, Merrill Lynch, and Deutsche Bank. His appointment is expected to strengthen the company’s governance and strategic direction.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics Announces Board Composition and Committee Roles

Cutia Therapeutics has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board has established three committees: the Audit Committee, Remuneration Committee, and Nomination Committee, each with designated members and chairpersons. This announcement reflects the company’s governance structure and may influence its strategic direction and stakeholder confidence.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics Forms Nomination Committee to Enhance Governance

Cutia Therapeutics announced the establishment of a Nomination Committee as part of its corporate governance structure. This committee, formed by the board of directors, aims to ensure diversity and independence in its membership, which may enhance the company’s decision-making processes and strengthen its governance framework.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics Announces Key Administrative Changes and Office Relocation

Cutia Therapeutics has announced a change in its company secretary, authorized representative, and process agent, with Ms. Chan Sze Ting resigning and Mr. Leung Chi Kit taking over the roles effective August 28, 2025. Additionally, the company has relocated its principal place of business in Hong Kong to a new address, indicating strategic operational adjustments.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics Advances in Dermatology with New Product Approvals

Cutia Therapeutics has announced significant advancements in its product pipeline and business operations for the first half of 2025. The company received marketing approval for its CU-40102 topical finasteride spray for androgenetic alopecia and CU-10201 topical minocycline foam for acne vulgaris from the NMPA, with CU-40102 also approved by the Hong Kong Department of Health. These approvals mark a milestone for Cutia, highlighting its innovative approach in the dermatology sector and paving the way for commercialization activities, potentially enhancing its market position and offering new treatment options for patients.

The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.

Cutia Therapeutics Schedules Board Meeting for Interim Results Review

Cutia Therapeutics has announced that its board of directors will hold a meeting on August 28, 2025, to consider and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also discuss the potential recommendation of an interim dividend and other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, as the interim results and any dividend decisions could impact investor confidence and market positioning.